Overview

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Status:
Not yet recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This study is an open label phase 2 study to evaluate the safety and efficacy of Lenvatinib with Pembrolizumab in the neoadjuvant / adjuvant treatment for Patients with Gastric Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Center Hospital East

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Lenvatinib
Pembrolizumab